https://www.thepharmaletter.com/biotech-news/astrazeneca-s-naloxegol-meets-endpoints-ema-validates-gilead-s-sofosbuvir-maa
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA | Biotechnology |...
Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal Phase III studies of naloxegol showing the 25mg dose of
astrazenecanaloxegolmeetsendpointsema